

Breast Tumor

Design and Development of a Targeted Molecular Probe for Ultrasensitive Early Detection of Breast Cancer

INDIAN PEPTIDE SOCIETY

Objective 3: Encapsulating the


Abhishek Kumar¹, Shritilekha Dash², Ramasamy Mayilmurugan^{1*}, Sharad Gupta^{2*}

¹ Department of Biological Science and Biomedical Engineering, Indian Institute of Technology Bhilai, Chhattisgarh, India-491002 ²Department of Biological Sciences and Engineering, Indian Institute of Technology, Gandhinagar, Gujarat, India-382355

Background

"While completely preventing breast cancer remains a challenge, but the casualties due to breast cancer can be reduced, through early detection."

According to the Global Cancer Observatory (ICAR-WHO, 2022), breast cancer is the most prevalent cancer worldwide, with an estimated 660,000 deaths among females in 2022. India recorded the highest number of estimated breast cancer fatalities, with ~100,000 deaths in the same year.



Stages Of Tumor And Role Of Cathepsin B (CSTB)

Objectives and Methodologies Objective 1: Probe Designing Objective 2: Probe Conjugation with Polymer

Resin

Amino Acid

Activation

Solid Phase
Peptide Synthesis

Deprotection

Results

with Polymer and Nanoparticle Synthesis

MRI Contrast agent with the Probe and Polymer conjugate

- Future Work

EDC/NHS


Overnight

A H₂0

Conjugate


Studies


- Synthesis of probe for CSTB using Solid Phase Peptide Synthesis and characterized with LC-MS and MALDI.
- Conjugation of Biomarker and 4arm-PEG5K Using EDC/NHS Coupling: Analysis via MALDI, FTIR, UV-Vis Spectrophotometry, and Zeta Potential Measurement.
- Probe's Nanoparticles synthesis and its characterization with SEM, EDS and DLS.




Size (d.nm):


FRRG-Pep 1 Approx mass = 1608.92 g/mol Approx mass = 1456.75 g/mol FT-IR WV-Vis Spectrophotometer Peptide — PEG — Conjugate SEM FGR-Pep 2 Approx mass = 1456.75 g/mol UV-Vis Spectrophotometer PEG — Conjugate










MRI Contrast Agent (SEM, EDS and DLS)









Conclusion

- A 12-amino acid peptide probe targeting Cathepsin B and a control peptide were synthesized using solid-phase peptide synthesis and characterized via LC-MS and MALDI.
- The peptides were conjugated with functionalized 4arm-PEG5K using EDC/NHS coupling, confirmed through FTIR, UV-Vis spectrophotometry, and zeta potential measurements.
- MRI contrast agent nanoparticles were synthesized and characterized using SEM, EDS and DLS meeting physicochemical criteria, with the next step involving *In-vitro* and *In-vivo* assays for biomarker targeting efficiency.

Acknowledgment

- I would like to express my sincere gratitude to Dr. Sharad Gupta, Dr. Ramasamy Mayilmurugan and Dr. Dhiraj Bhatia, for their invaluable guidance and encouragement throughout this research.
- I also extend my thanks to my colleagues Shritilekha Dash, Sebika Panja, Abhijit Biswas, Ashish Kumar Samal, and SG Lab members for their guidance and support.
- Finally, I am grateful to the organizers of the Indian Peptide Symposium for providing this platform to present my research.

References

- Xu, Y., Gong, M., Wang, Y. et al. Sci Data 10, 334 (2023). https://doi.org/10.1038/s41597-023-02253-5
- Kulothungan, V., Ramamoorthy, T., Sathishkumar, K. et al. Breast Cancer Res Treat 205, 323–332 (2024). https://doi.org/10.1007/s10549-024-07264-3
- Chen, W., Hoffmann, A.D., Liu, H. et al. npj Precision Onc 2, 4 (2018). https://doi.org/10.1038/s41698-018-0047-0
- Balcı, B., Top, A. J Polym Res 25, 104 (2018). https://doi.org/10.1007/s10965-018-1506-6
- https://www.who.int/news-room/fact-sheets/detail/breast-cancer



St Dev (d.n..

% Intensity:

